Simon
Pedder, Ph.D.
President and CEO Key Compounds: Tasmar ®, Pegasys ®, Copegus ®
Dr. Pedder joined Chelsea from Hoffmann-La Roche Inc. where he was
VP of Pharmaceutical Business, Oncology and an Officer for the company.
Prior to that he was in charge of the hepatitis franchise at Roche
where he was in charge of the development of Pegasys and Copegus,
which have combined annual worldwide sales of over $1 billion. He
has been a Director in Pharmaceutical Business, Pharmaceutical Development
and Project Management. During his time at Roche he oversaw a number
of successful NDAs. Dr. Pedder has his Ph.D. in Pharmacology from
the College of Medicine at the University of Saskatchewan in Canada.
(top)
L.
Arthur Hewitt, Ph.D. Chief Scientific Officer Key Compounds: Epogen ®, Infergen ®
Dr. Hewitt has over 30 years of pharmaceutical industry experience working for Abbott Laboratories, Parke-Davis, Janssen Pharmaceuticals and Amgen. While at Amgen he was the Head of Clinical Research and Regulatory Affairs in Canada. During his years at Amgen, Dr. Hewitt oversaw the establishment of thirteen individual IND research programs (in hematology, oncology, neurology, infectious disease and inflammation), the approval process for three NCEs (Neupogen, Infergen, Stemgen) as well as six supplementary approvals for additional claims for the use of Neupogen. Dr. Hewitt obtained his Ph.D. in Pharmacology from the Medical School at the University of Montreal. (top)
J.
Nick Riehle, M.B.A Vice President, Administration and CFO
Mr. Riehle has over 25 years of business and management experience
with both large fortune 500 companies and start-up ventures. He has
held senior positions at HAHT Commerce and Nortel Networks. In addition
he has had significant success with regards to venture financing,
growing business volume and improving profitability. Mr. Riehle earned
his Bachelor of Commerce from McGill University, his MBA from York
University and a Certified Management Accountant (CMA) designation
in Ontario, Canada. (top)
Mr. Schmidt brings to Chelsea over 25 years of experience and a
proven track record in domestic and international pharmaceutical
sales and strategic marketing for launching industry leading drugs
including Pegasys ™, Naprosyn ™, Anaprox ™, Cialis ™,
Cymbalta ™, and Strattera™. Over the course of his career,
Mr. Schmidt has worked for companies such as Hoffmann–La Roche
and Syntex Laboratories and served as the Vice President assigned
to Eli Lilly marketing for Thomson Advanced Therapeutics Communications.
During his tenure at Hoffmann-La Roche, Mr. Schmidt served as International
Business Leader responsible for global pre-launch marketing preparation,
launch market plans, and life cycle planning for Pegasys™ in
Hepatitis. Prior to joining Roche, Mr. Schmidt served in a number
of progressively senior positions at Syntex Laboratories variously
directing New Product Development, Sales Force Strategies, OBYN Sales,
and Sales Training. Mr. Schmidt has a BS in Experimental Psychology
and an MBA in International Marketing from the University of San
Francisco. (top)
Joseph G. Oliveto, M.B.A Vice President, Operations
Key Compounds: Pegasys®, Copegus®, Xenical®
Mr. Oliveto joined Chelsea following a two-year assignment as Executive in Residence at Pappas Ventures, a life sciences venture capital firm. Prior to Pappas Ventures, he served in a number of progressively senior positions at Hoffmann-La Roche, most recently as the Global Alliance Director for Roche's licensing organization. Previous experience at Roche includes clinical development, project management, manufacturing process improvement and global business. During his tenure, he played an integral part in the success of multiple NDA filings, developed comprehensive launch programs, including those for both Pegasys and CoPegus, and closed multiple licensing deals. Mr. Oliveto obtained a BA in Chemistry and an MBA from Rutgers University. (top)
William D. Schwieterman, M.D. Chief Medical Officer
Dr. Schwieterman joined the company as an employee and officer in October 2009 after serving for more than a year on our Board of Directors and several years as a consultant and member of the company’s Scientific Advisory Board. He is a rheumatologist and board-certified internist who was formerly Chief of the Medicine Branch and Chief of the Immunology and Infectious Disease Branch in the Division of Clinical Trials at the FDA. In these capacities and others, Dr. Schwieterman spent 10 years at the FDA in the Center for Biologics overseeing a wide range of clinical development plans for a large number of different types of molecules. Dr. Schwieterman helped author the FDA's "Good Review Practices" for investigational products, and was instrumental in developing several guidance documents for the industry. Since leaving the FDA, he has acted as an independent consultant to biotechnology and pharmaceutical companies, focusing on clinical drug development and regulatory matters. Dr. Schwieterman holds a B.S. and M.D. from the University of Cincinnati. (top)
Michael
J. Roberts, Ph.D. Vice President, Business Development
Key Compounds: Macugen ®, PEG-Intron ®, Neulasta ®
Dr. Roberts joined Chelsea from Nektar Therapeutics where he was
Director of Business Development for their Molecule Engineering technology.
Prior to this he was Manager of Biopharmaceutical Research at Shearwater
Corporation where he lead and was successful in the development of
preclinical drug candidates from initial stages of research through
Phase I clinical study. Dr. Roberts obtained his Ph.D. in Materials
Science from the University of Alabama in Huntsville and B.S. in
Chemical Engineering from Pennsylvania State University. (top)
Cameron
Szakacs, Ph.D. Senior Director, Drug Development Key Compounds: Herceptin ®, MabThera ®/
Rituxan ®
Dr. Szakacs joined Chelsea Therapeutics from Nektar Therapeutics
where he was responsible for running preclinical programs, including
toxicology, safety pharmacology and proof-of-concept efficacy studies. Previously,
Dr. Szakacs oversaw clinical development programs for Endpoint Research
(a Canadian clinical research organization) as a Project Director
with an emphasis on oncology molecules. Previously he had worked
for 5 years with Hoffmann La-Roche in numerous capacities within
their Development organization. Dr. Szakacs also taught, and conducted
both animal and human pharmacology research at the University of
Saskatchewan, where he received his Ph.D. in Pharmacology. (top)
J.
Nick Riehle, M.B.A
